| (Values in U.S. Thousands) | Jun, 2017 | Mar, 2017 | Dec, 2016 | Sep, 2016 | Jun, 2016 |
| Sales | -9,999,000 | 17,110 | 19,530 | 22,570 | 19,910 |
| Sales Growth | -58,539.51% | -12.39% | -13.47% | +13.36% | +38.65% |
| Net Income | -9,999,000 | -890 | -4,730 | -40 | -3,920 |
| Net Income Growth | -1,123,384.41% | +81.18% | -11,725.30% | +98.98% | -56.80% |
Merus Labs Intl Inc (MSLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Merus Labs International Inc. is a specialty pharmaceutical company engaged in acquisition and licensing of pharmaceutical products. The Company's products include anti-infectives and wound care products. Merus Labs International Inc., formerly known as Envoy Capital Group Inc., is based in Vancouver, Canada.
Fiscal Year End Date: 09/30